91 related articles for article (PubMed ID: 21924845)
1. Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
Schwappach D; Popova S; Mohapatra S; Patra J; Godinho A; Rehm J
Drug Alcohol Depend; 2012 May; 122(3):165-73. PubMed ID: 21924845
[TBL] [Abstract][Full Text] [Related]
2. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Baser O; Chalk M; Rawson R; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
[TBL] [Abstract][Full Text] [Related]
3. A literature review of cost-benefit analyses for the treatment of alcohol dependence.
Popova S; Mohapatra S; Patra J; Duhig A; Rehm J
Int J Environ Res Public Health; 2011 Aug; 8(8):3351-64. PubMed ID: 21909311
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence.
Navarro HJ; Shakeshaft A; Doran CM; Petrie DJ
Drug Alcohol Depend; 2012 Aug; 124(3):207-15. PubMed ID: 22361211
[TBL] [Abstract][Full Text] [Related]
5. A critical review of pharmacoeconomic studies of acamprosate.
Poldrugo F; Haeger DA; Comte S; Walburg J; Palmer AJ
Alcohol Alcohol; 2005; 40(5):422-30. PubMed ID: 15939706
[TBL] [Abstract][Full Text] [Related]
6. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
[TBL] [Abstract][Full Text] [Related]
7. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations.
Mason BJ; Crean R
Expert Rev Neurother; 2007 Nov; 7(11):1465-77. PubMed ID: 17997696
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Snyder JL; Bowers TG
Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
[TBL] [Abstract][Full Text] [Related]
9. Measuring economic outcomes of alcohol treatment using the Economic Form 90.
Bray JW; Zarkin GA; Miller WR; Mitra D; Kivlahan DR; Martin DJ; Couper DJ; Cisler RA
J Stud Alcohol Drugs; 2007 Mar; 68(2):248-55. PubMed ID: 17286343
[TBL] [Abstract][Full Text] [Related]
10. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care.
Kiritzé-Topor P; Huas D; Rosenzweig C; Comte S; Paille F; Lehert P
Alcohol Alcohol; 2004; 39(6):520-7. PubMed ID: 15304381
[TBL] [Abstract][Full Text] [Related]
11. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
12. The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence.
Walters D; Connor JP; Feeney GF; Young RM
J Addict Dis; 2009; 28(2):137-44. PubMed ID: 19340676
[TBL] [Abstract][Full Text] [Related]
13. New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
Doran CM; Fawcett JE; Shakeshaft AP; Shanahan MD; Mattick RP
Med J Aust; 2003 Aug; 179(4):218. PubMed ID: 12914502
[No Abstract] [Full Text] [Related]
14. Acamprosate for the treatment of alcohol dependence.
Boothby LA; Doering PL
Clin Ther; 2005 Jun; 27(6):695-714. PubMed ID: 16117977
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
Dunlap LJ; Zarkin GA; Bray JW; Mills M; Kivlahan DR; McKay JR; Latham P; Tonigan JS
Med Care; 2010 Apr; 48(4):306-13. PubMed ID: 20355261
[TBL] [Abstract][Full Text] [Related]
16. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Rösner S; Leucht S; Lehert P; Soyka M
J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
[TBL] [Abstract][Full Text] [Related]
17. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
Buri C; Moggi F; Giovanoli A; Strik W
Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
[TBL] [Abstract][Full Text] [Related]
18. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy: what does acamprosate and naltrexone combination tell us?
Kiefer F; Wiedemann K
Alcohol Alcohol; 2004; 39(6):542-7. PubMed ID: 15456690
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.
Schädlich PK; Brecht JG
Pharmacoeconomics; 1998 Jun; 13(6):719-30. PubMed ID: 10179707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
